mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development.

The journal has a strong scientific and medical focus but serves a broad readership, including specialists in technology transfer, legal issues, investment, planning and the regulation of therapeutics.

mAbs covers a range of topics, including:

    Engineering and selection of antibody therapeutics, including antibody-drug conjugates, multispecific andtibodies, and single-domain antibodies
    Machine learning and artificial intelligence applications
    Non-clinical studies of antibodies, such as mechanism of action studies, safety and efficacy studies in animals
    Manufacturing and formulation
    Regulatory review of antibody therapeutics
    Post-approval topics, such as markets

mAbs accepts original research papers, brief reports, short communications, reviews, perspectives, commentaries, meeting reports, and article addenda.

The journal operates a single-anonymized peer review policy. All articles will be made freely and permanently available online through gold open access publication.



*Please note that mAbs converted to a fully Open Access journal beginning with Volume 12 (2020). The 2009-2020 volumes will be free to access from 1 January 2021 .